Glyburide: Difference between revisions
Jump to navigation
Jump to search
NCLEX nursing pharmacology monographs — batch import |
Add medication infobox (Drugbox) to monographs |
||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| name = Glyburide | |||
| brand = DiaBeta | |||
| therapeutic = Antidiabetic | |||
| pharmacologic = Second-generation sulfonylurea | |||
| onset = Onset 1 hour; duration up to 24 hours. | |||
| halflife = Half-life about 10 hours; no routine level. | |||
| routes = PO (oral) | |||
| highalert = No | |||
| blackbox = <span style="color:#b00020;">'''Yes'''</span> (see Safety) | |||
| antidote = Glucose or glucagon. | |||
| pregnancy = Generally avoided. | |||
}} | |||
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | <div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | ||
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ||
Latest revision as of 16:09, 17 June 2026
| Drug monograph · NCLEX study reference | |
| Trade names | DiaBeta |
|---|---|
| Therapeutic class | Antidiabetic |
| Pharmacologic class | Second-generation sulfonylurea |
| Onset / peak / duration | Onset 1 hour; duration up to 24 hours. |
| Half-life / level | Half-life about 10 hours; no routine level. |
| Routes | PO (oral) |
| High-alert (ISMP) | No |
| Black box warning | Yes (see Safety) |
| Antidote / reversal | Glucose or glucagon. |
| Pregnancy / lactation | Generally avoided. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Glyburide (brand name DiaBeta) — Antidiabetic; Second-generation sulfonylurea.
Identification
- Therapeutic class: Antidiabetic.
- Pharmacologic class: Second-generation sulfonylurea.
Pharmacology
- Mechanism of action: Stimulates insulin secretion; longer acting with higher hypoglycemia risk in elderly.
- Onset / peak / duration: Onset 1 hour; duration up to 24 hours.
- Half-life / therapeutic level: Half-life about 10 hours; no routine level.
Clinical use
- Indications: Type 2 diabetes.
- Usual dose, route, frequency: 1.25 to 10 mg PO once or twice daily.
- Maximum dose / adjustments: Max about 20 mg/day; avoid in elderly and significant renal impairment due to prolonged hypoglycemia.
Safety
- Contraindications: Type 1 diabetes, ketoacidosis, sulfonamide hypersensitivity, severe renal impairment.
- Black box warning: Sulfonylurea class cardiovascular mortality caution (older labeling).
- Interactions: Same as other sulfonylureas.
- Pregnancy / lactation: Generally avoided.
- High-alert: No.
Adverse effects
- Common side effects: Hypoglycemia, weight gain.
- Serious effects to report: Prolonged severe hypoglycemia.
- Antidote / reversal: Glucose or glucagon.
Nursing process
- Assessment before administration: Blood glucose, renal function, age.
- Interventions during therapy: Caution in older adults; monitor for delayed lows.
- Monitor: Blood glucose, A1c.
- Evaluation / expected outcome: Glycemic control.
Patient teaching
- Patient teaching: Take with meals; watch for lows.
- Notify provider if: Frequent or prolonged lows.
- Administration tips: With food.